Company profile: Alder BioPharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical solutions leveraging proprietary technologies to accelerate antibody discovery and development. The company identifies, develops, produces, and markets its own antibody therapeutics aimed at generating better and safer treatments.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alder BioPharmaceuticals
Kyverna Therapeutics
HQ: United States
Website
- Description: Provider of autologous and allogeneic anti-CD19 CAR T-cell therapies for B-cell-driven autoimmune diseases, including KYV-101 and KYV-201. Offers clinical trials in lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis, plus an expanded access program, using engineered T cells to potentially reset the immune system and achieve sustained remission.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kyverna Therapeutics company profile →
Curevo Vaccine
HQ: United States
Website
- Description: Provider of next-generation, non-mRNA vaccines for infectious diseases, developing Amezosvatein for the prevention of shingles and chickenpox.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Curevo Vaccine company profile →
Diamyd Medical
HQ: Sweden
Website
- Description: Provider of antigen-specific immunotherapies and regenerative therapies for Type 1 Diabetes based on the GAD molecule and GABA technology. Products include Diamyd to preserve insulin production and Remygen for regeneration/immunomodulation. Offers GMP-manufactured GAD65 protein for preclinical research and conducts DIAGNODE-3 (Phase III intralymphatic Diamyd) and DiaPrecise (Phase II prevention) trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diamyd Medical company profile →
Eureka Therapeutics
HQ: United States
Website
- Description: Provider of T-cell therapies via the ARTEMIS Cell Receptor Platform to engineer T cells to target and destroy cancer cells; the E-ALPHA Phage Display Platform to generate specific antibodies against cancer targets, including TCR-mimic antibodies for solid tumors; and an Expanded Access Policy offering investigational cell therapy under certain conditions to patients with serious or life-threatening diseases who have no other treatment options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eureka Therapeutics company profile →
Bavarian Nordic
HQ: Denmark
Website
- Description: Provider of novel vaccines for the treatment and prevention of life-threatening diseases with large unmet medical need, focused on biodefence, cancer and infectious diseases. Product portfolio includes MVA-BN, a non-replicating vaccine for immunization against smallpox and mpox, approved in various countries and supplied to national stockpiles.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bavarian Nordic company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alder BioPharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alder BioPharmaceuticals
2.2 - Growth funds investing in similar companies to Alder BioPharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alder BioPharmaceuticals
4.2 - Public trading comparable groups for Alder BioPharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →